Three Dose Regimen of Tranexamic Acid in Cardiac Surgery

• Status: Unknown status
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Tranexamic acid is thought to be a promising substitute for aprotinin when the latter has seceded in 2007. Yet the ideal dosage and dosing regimen of tranexamic acid in cardiopulmonary bypass cardiac surgery in Chinese population remains controversial. The current study includes patients receiving valvular replacement and coronary artery bypass surgery. Three dosage regimen of tranexamic acid is delivered and blood loss, transfusions and clinical outcomes are recorded.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• Rheumatic or recessive valvular disease patients requiring valvular replacement surgery with cardiopulmonary bypass

• Coronary artery disease patients requiring coronary artery bypass surgery with cardiopulmonary bypass

• Wrriten consent obtained

Exclusion Criteria:

• Non-primary cardiac surgery

• Preoperative liver or renal dysfunction

• Preoperative coagulation disorder

• Allergy

• Pregnancy or lactation

• Disabled in spirit or law

• Fatal conditions such as tumour